Collaboration Growth The merger of Inova and IN-PART creates a unified platform serving pharma, biotech, and academia, unlocking cross-segment upsell opportunities such as broader licenses, more seats, and expanded collaboration management modules.

Channel Partnership The Evaluate partnership signals a scalable go-to-market through channel partners to reach biopharma decision-makers, with potential to co-sell and bundle AI powered deal optimization tools.

AI and Integration With OpenAI and enterprise-grade integrations for Microsoft 365 and security tooling, there is a strong opportunity to position AI assisted matchmaking, automated deal workflows, and secure collaboration as premium offerings.

EU Midmarket Based in France with a mid sized team, Inpart can target EU research institutions and pharma partners requiring regulatory compliant data sharing, tailoring offerings for EU R&D collaborations and public private partnerships.

Deal Optimization The focus on biopharma dealmaking and partnership optimization indicates buyers’ need for end to end deal flow, IP management, and performance analytics, suggesting opportunities for contract management add ons and professional services.